[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"jc-virus-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:jc-virus-infection":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100245918","phase-2-cytotoxic-t-lymphocytes-in-treating-patients-with-malignancies-with-bk-andor-jc-virus-100245918",false,"NCT02479698","Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and\u002For JC Virus","Phase II Study Assessing the Effect of BK Specific CTL Lines Generated by Ex Vivo Expansion in Patients With BK Virus Infection and JC Virus Infection","Inclusion Criteria:\n\n* Patients ≥ 2 years.\n* English and non-English speaking patients are eligible.\n* Immunocompromised patients including but not limited to those with any type of malignancy, HIV\u002FAIDS, or history of solid organ transplant\n* Non-immunocompromised patients with PML\u002FJC virus encephalitis\n* Microscopic or greater hematuria urine or blood PCR positive for BK virus\n* Biopsy proven BK nephritis and urine or blood PCR positive for BK virus disease and\u002For polyomavirus.\n* Definite or probable PML\u002FJC viral encephalitis (see Appendix C)\n* JC end-organ disease\n* Receiving \\> 6 mg \u002F day of prednisone or equivalent at the time of enrollment.\n* Patients with BK virus hemorrhagic cystitis, who are receiving treatment with cidofovir, leflunomide, or other antiviral therapy with no response, will be eligible for CTL infusion.\n* Patients with JCV encephalitis \u002F PML may be receiving pembrolizumab.\n* Written informed consent and\u002For signed assent from patient, parent or guardian.\n* Patients with cognitive impairments are eligible.\n* A negative pregnancy test in female patients of childbearing potential. Childbearing potential is defined as pre-menopausal, post-menopausal for \\\u003C 1 year, and not having undergone surgical sterilization.\n* Women of childbearing potential must be willing to use an effective contraceptive measure while on study.\n* Patients enrolled on this study may be enrolled on other IND studies at the discretion of the PI.\n* Patients with bacterial infections must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment.\n* Patients with fungal infections patients must be receiving definitive systemic anti fungal therapy and have no signs of progressing infection for 1 week prior to enrollment.\n* Patients may be re-enrolled in the protocol if the BK or JC virus infection recurs, so long as they meet all the other eligibility criteria at the time of re-enrollment.\n\nExclusion Criteria:\n\n* Patients receiving \\> 6 mg \u002F day of prednisone or equivalent at time of\n* Patients who have received ATG within 14 days of enrollment\n* Patients who have received donor lymphocyte infusion (DLI) within 28 days of enrollment.\n* Patients who have received alemtuzumab within 28 days of enrollment.\n* Patients with other uncontrolled infections (including HIV\u002FAIDS). Uncontrolled infection is defined as the presence of hemodynamic instability attributable to sepsis, or new symptoms, worsening physical signs, or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as uncontrolled infection.\n* Patients with active acute GVHD grades II-IV.","ALL",{"count":18,"type":19},100,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","This phase II trial studies how well donor cytotoxic T lymphocytes work in treating patients with malignancies with BK and\u002For JC virus. Cytotoxic T lymphocytes are made from donated blood cells that are grown in the laboratory and are designed to kill viruses that can cause infections in transplant patients and may be an effective treatment in patients with malignancies with BK and\u002For JC virus.",[25,26,27,28,29,30,31,32],"Acquired Immunodeficiency Syndrome","BK Virus Infection","Human Immunodeficiency Virus","JC Virus Infection","Malignant Neoplasm","Merkel Cell Carcinoma","Merkel Cell Polyomavirus Infection","Viral Encephalitis","RECRUITING","2026-08-19",{"date":36,"type":37},"2026-08-21","ACTUAL",{"date":39,"type":37},"2015-07-23",{"date":41,"type":19},"2027-07-31",{"name":43,"class":44},"M.D. Anderson Cancer Center","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":53,"enrollmentInfo":4,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":66,"locationsCount":4},"100600984","tetravi-expanded-access-program-100600984","NCT07104591","TETRAVI Expanded Access Program","Expanded Access Use of Multivirus-Specific Cytotoxic T-Lymphocytes for Pediatric Patients With EBV, CMV, Adenovirus, or BK Virus Infections Post Allogeneic Stem Cell Transplant","Inclusion Criteria:\n\n* Patients \\\u003C18 years of age.\n* Patients who have undergone myeloablative or non-myeloablative allogeneic HSCT or CAR T therapy in the Sate of Texas (USA).\n* Have persistent, increasing, or recurrent infections with EBV, CMV, adenovirus, or BK virus despite standard treatment.\n* Treating physician must be based in Texas.\n* Must obtain IRB approval and submit a protocol to FDA with Letter of Authorization from Baylor.\n\nExclusion Criteria:\n\n* Patients with active uncontrolled infections unrelated to the viruses mentioned.\n* Use of certain immunosuppressive agents within 28 days.\n* Serious uncontrolled medical conditions or relapse of underlying disease.","17 Years","EXPANDED_ACCESS","This Expanded Access Program (EAP) allows qualified physicians within Texas to obtain access to multivirus-specific cytotoxic T lymphocytes (VSTs) developed under Baylor College of Medicine's TETRAVI program (NCT04013802) for the treatment of persistent or recurrent infections with EBV, CMV, adenovirus, or BK virus in pediatric patients being treated in Texas who have received allogeneic stem cell transplants and have no other suitable therapeutic options.",[57,58,59,26,28,60,61],"Epstein-Barr Virus Infection","Cytomegalovirus Infections","Adenovirus Infection","Viral Infections Post-Transplant","Post-Allogeneic Stem Cell Transplant Complications","AVAILABLE","2025-07-29",{"date":65,"type":37},"2025-08-05",{"name":67,"class":44},"Baylor College of Medicine"]